Immuno-Oncology | Specialty

Pembrolizumab Shows Robust Activity in Head and Neck Cancer

June 10th 2016

Pembrolizumab demonstrated an objective response rate of 18% in data from two clinical trials exploring the PD-1 inhibitor as a treatment for patients with pretreated recurrent or metastatic head and neck squamous cell carcinoma.

Expert Addresses Sequencing and Resistance With Immunotherapy in Melanoma

June 10th 2016

Keith T. Flaherty, MD, discusses choosing between immunotherapy and targeted therapy in the frontline setting for patients with BRAF-mutated melanoma.

Avelumab Highly Effective in Metastatic Merkel Cell Carcinoma

June 8th 2016

The PD-L1 inhibitor avelumab demonstrated durable responses and promising early survival data for patients with pretreated metastatic Merkel cell carcinoma.

High Response Rates Achieved with Pembrolizumab in Refractory Hodgkin Lymphoma

June 7th 2016

Pembrolizumab (Keytruda) is associated with an exceptional overall response rate in patients with relapsed/refractory Hodgkin lymphoma.

Dr. Ferris on Significance of CheckMate-141 Trial for Head and Neck Cancer

June 7th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).

Long-Term Follow-up Sustains Frontline Nivolumab/Ipilimumab Benefit in Melanoma

June 7th 2016

At a minimum follow-up of 18 months, the combination of nivolumab and ipilimumab reduced the risk of disease progression by 58% compared with ipilimumab alone, and single-agent nivolumab lowered the risk of progression by 45% versus ipilimumab monotherapy in patients with advanced melanoma.

Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma

June 7th 2016

David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).

PD-L1 Inhibitor Avelumab Active in Advanced Mesothelioma

June 7th 2016

Avelumab demonstrated clinical activity in patients with advanced or unresectable mesothelioma, with an overall response rate of 14.3%.

Nivolumab Improves OS, ORR in Phase III Head and Neck Cancer Study

June 7th 2016

Treatment with single-agent nivolumab improved overall survival and objective response rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Nivolumab Delivers Durable Responses in Hodgkin Lymphoma

June 6th 2016

Single-agent nivolumab induced responses in 66% of patients with classical Hodgkin lymphoma who had progressed following autologous stem cell transplant and brentuximab vedotin.

Nivolumab 5-Year OS Rate Passes 30% in Advanced RCC

June 6th 2016

About one third of patients with advanced renal cell carcinoma who were treated with single-agent nivolumab in the second-line setting or later were still alive at 4 and 5 years in long-term follow-up data from phase I and phase II clinical trials.

Atezolizumab Effective in First-Line Setting in Bladder Cancer

June 6th 2016

Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).

Bernard Fox on Significance of Immunoscore Validation Project

June 6th 2016

Bernard A. Fox, PhD, chief, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute at Providence Portland Medical Center, discusses the significance of the Immunoscore Validation Project.

Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma

June 6th 2016

Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.

Novel Gastric Cancer Immunotherapy Scores Robust Phase II Results

June 6th 2016

IMAB362 reduced the risk of death or progression by approximately 50% when added to standard chemotherapy for patients with CLDN18.2-positive advanced gastric cancers.

Nivolumab/Ipilimumab Combo Active in Microsatellite Instability-High mCRC

June 6th 2016

Nivolumab (Opdivo) as a monotherapy and in combination with ipilimumab (Yervoy) demonstrated promising antitumor activity in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.

Nivolumab/Ipilimumab Frontline Response Nears 60% in PD-L1+ NSCLC

June 5th 2016

Upfront treatment with the combination of nivolumab and ipilimumab demonstrated an objective response rate of 57% in patients with PD-L1-positive advanced non–small cell lung cancer.

Adding 4-1BB Agonist to Pembrolizumab Safe, Effective Across Solid Tumors

June 5th 2016

The combination of the 4-1BB agonist utomilumab and the PD-1 inhibitor pembrolizumab was safe and effective as a treatment for patients with advanced solid tumors.

Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes

June 5th 2016

Two-year follow-up data showed sustained improvements in overall survival with nivolumab in pretreated patients with either nonsquamous or squamous non–small cell lung cancer in updated findings from the phase III CheckMate-057 and -017 trials.

Nivolumab Safe, Effective in Early Stage Glioblastoma Study

June 5th 2016

Single-agent nivolumab demonstrated encouraging signs of activity with a mild adverse event profile for patients with recurrent glioblastoma multiforme.